NORTH BILLERICA, Mass.--(BUSINESS WIRE)--Nov. 28, 2018--
Lantheus
Holdings, Inc. (the “Company”) (NASDAQ: LNTH), the parent company of Lantheus
Medical Imaging, Inc. (“LMI”), a global leader in the development,
manufacture and commercialization of innovative diagnostic imaging
agents and products, today announced Mary Anne Heino, President and
Chief Executive Officer, will present at the BMO Prescriptions for
Success Healthcare Conference on Wednesday, December 12, 2018 at 3:00
p.m. Eastern in New York City.
To access a live webcast of the presentation, please visit the Investors
section of the Company’s website at www.lantheus.com.
A replay of the webcast will be available on the Company’s website for
30 days following the live presentation.
About Lantheus Holdings, Inc. and Lantheus Medical Imaging, Inc.
Lantheus
Holdings, Inc. is the parent company of LMI, a global leader in the
development, manufacture and commercialization of innovative diagnostic
imaging agents and products. LMI provides a broad portfolio of products,
including the echocardiography contrast agent DEFINITY® Vial
for (Perflutren Lipid Microsphere) Injectable Suspension; TechneLite®
(Technetium Tc99m Generator), a technetium-based generator that provides
the essential medical isotope used in nuclear medicine procedures; and
Xenon (Xenon Xe 133 Gas), an inhaled radiopharmaceutical imaging agent
used to evaluate pulmonary function and for imaging the lungs. The
Company is headquartered in North Billerica, Massachusetts with offices
in Puerto Rico and Canada. For more information, visit www.lantheus.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181128005615/en/
Source: Lantheus Holdings, Inc.
Meara Murphy
Director, Investor Relations & Corporate Communications
978-671-8508
